| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.619 | 0.009 | 0.624 | Caspase 3 stimulant | 0.624 0.009 DBMET01532 | DBMET01532 | |
| 0.622 | 0.013 | 0.765 | Aryl hydrocarbon receptor agonist | 0.765 0.007 DBMET01532 | DBMET01532 | |
| 0.506 | 0.031 | 0.506 | Immunosuppressant | 0.427 0.054 DBMET01532 | ||
| 0.474 | 0.004 | 0.474 | Glutamate receptor agonist | 0.123 0.025 DBMET01532 | ||
| 0.45 | 0.003 | 0.45 | Sphingosine 1-phosphate receptor 5 agonist | 0.194 0.004 DBMET01532 | ||
| 0.481 | 0.043 | 0.481 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.485 | 0.055 | 0.487 | Cyclophilin D inhibitor | 0.487 0.054 DBMET01532 | DBMET01532 | |
| 0.415 | 0.003 | 0.415 | Sphingosine 1-phosphate receptor antagonist | 0.187 0.005 DBMET01532 | ||
| 0.427 | 0.016 | 0.427 | Pyruvate kinase inhibitor | 0.357 0.031 DBMET01532 | ||
| 0.405 | 0.002 | 0.405 | Sphingosine 1-phosphate receptor agonist | 0.131 0.004 DBMET01532 | ||
| 0.402 | 0.001 | 0.402 | DOPA decarboxylase inhibitor | 0.314 0.002 DBMET01532 | ||
| 0.392 | 0.016 | 0.392 | 5 Hydroxytryptamine uptake stimulant | 0.211 0.132 DBMET01532 | ||
| 0.361 | 0.004 | 0.361 | Sphingosine 1-phosphate receptor 2 agonist | 0.264 0.005 DBMET01532 | ||
| 0.359 | 0.003 | 0.359 | Sphingosine 1-phosphate receptor 4 antagonist | 0.177 0.016 DBMET01532 | ||
| 0.346 | 0.005 | 0.346 | Ferrochelatase inhibitor | |||
| 0.343 | 0.002 | 0.343 | Sphingosine 1-phosphate receptor 5 antagonist | 0.21 0.008 DBMET01532 | ||
| 0.343 | 0.005 | 0.343 | Glutamate (mGluR) agonist | 0.125 0.018 DBMET01532 | ||
| 0.332 | 0.002 | 0.332 | Sphingosine 1-phosphate receptor 3 agonist | 0.175 0.004 DBMET01532 | ||
| 0.293 | 0.003 | 0.293 | Sphingosine 1-phosphate receptor 1 antagonist | 0.134 0.005 DBMET01532 | ||
| 0.414 | 0.131 | 0.568 | Antiinflammatory | 0.568 0.063 DBMET01532 | DBMET01532 | |
| 0.321 | 0.045 | 0.321 | Transcription factor STAT inhibitor | 0.228 0.104 DBMET01532 | ||
| 0.308 | 0.038 | 0.308 | Anticonvulsant | |||
| 0.256 | 0.003 | 0.256 | Sphingosine 1-phosphate receptor 1 agonist | 0.079 0.006 DBMET01532 | ||
| 0.267 | 0.029 | 0.267 | I kappa B kinase epsilon inhibitor | |||
| 0.222 | 0.005 | 0.222 | Transcription factor STAT6 inhibitor | 0.107 0.087 DBMET01532 | ||
| 0.234 | 0.018 | 0.234 | Glutamate receptor antagonist | |||
| 0.231 | 0.02 | 0.231 | Cell wall synthesis inhibitor | 0.163 0.054 DBMET01532 | ||
| 0.221 | 0.016 | 0.221 | Farnesoid X receptor antagonist | 0.185 0.027 DBMET01532 | ||
| 0.223 | 0.023 | 0.223 | Aldehyde dehydrogenase inhibitor | |||
| 0.207 | 0.009 | 0.207 | Glutamate (mGluR) antagonist | |||
| 0.197 | 0.003 | 0.197 | Sphingosine 1-phosphate receptor 3 antagonist | 0.09 0.011 DBMET01532 | ||
| 0.328 | 0.136 | 0.328 | 5 Hydroxytryptamine release inhibitor | |||
| 0.193 | 0.004 | 0.193 | Glutamate (mGluR group I) agonist | 0.053 0.028 DBMET01532 | ||
| 0.191 | 0.002 | 0.191 | Carnitine palmitoyltransferase inhibitor | 0.043 0.013 DBMET01532 | ||
| 0.217 | 0.029 | 0.217 | Alpha-N-acetylglucosaminidase inhibitor | |||
| 0.189 | 0.003 | 0.189 | Carnitine palmitoyltransferase 1A inhibitor | 0.072 0.004 DBMET01532 | ||
| 0.181 | 0.005 | 0.181 | Sphingosine 1-phosphate receptor 4 agonist | 0.087 0.032 DBMET01532 | ||
| 0.19 | 0.017 | 0.19 | Potassium channel (Ca-activated) activator | |||
| 0.174 | 0.002 | 0.174 | Carnitine palmitoyltransferase 1 inhibitor | 0.042 0.014 DBMET01532 | ||
| 0.19 | 0.022 | 0.19 | GABA C receptor agonist | |||
| 0.284 | 0.127 | 0.284 | GABA C receptor rho-3 antagonist | |||
| 0.207 | 0.06 | 0.207 | Histone acetyltransferase inhibitor | |||
| 0.19 | 0.045 | 0.19 | NOS3 expression enhancer | 0.143 0.08 DBMET01532 | ||
| 0.276 | 0.134 | 0.276 | Antiobesity | |||
| 0.198 | 0.058 | 0.198 | Lipocortins synthesis antagonist | |||
| 0.181 | 0.042 | 0.183 | Mannose-6-phosphate isomerase inhibitor | 0.183 0.04 DBMET01532 | DBMET01532 | |
| 0.141 | 0.004 | 0.141 | Nicotinic acid receptor agonist | |||
| 0.15 | 0.014 | 0.15 | Glutamate (mGluR group I) antagonist | |||
| 0.139 | 0.004 | 0.139 | Glutamate (mGluR5) agonist | 0.045 0.032 DBMET01532 | ||
| 0.137 | 0.004 | 0.137 | Glutamate (mGluR group II) antagonist | 0.038 0.027 DBMET01532 | ||
| 0.14 | 0.01 | 0.14 | Benzodiazepine agonist | 0.064 0.06 DBMET01532 | ||
| 0.13 | 0.003 | 0.13 | Retinoic acid beta receptor agonist | 0.032 0.005 DBMET01532 | ||
| 0.133 | 0.012 | 0.133 | Bile acid receptor antagonist | 0.117 0.022 DBMET01532 | ||
| 0.149 | 0.029 | 0.149 | Caspase 3 inhibitor | |||
| 0.14 | 0.024 | 0.14 | Alcohol dehydrogenase inhibitor | |||
| 0.116 | 0.005 | 0.116 | Sphingosine kinase 2 inhibitor | 0.099 0.008 DBMET01532 | ||
| 0.236 | 0.127 | 0.236 | Immunomodulator | |||
| 0.11 | 0.004 | 0.11 | Glutamate (mGluR2) antagonist | 0.027 0.025 DBMET01532 | ||
| 0.11 | 0.004 | 0.11 | Farnesoid X receptor agonist | 0.036 0.029 DBMET01532 | ||
| 0.113 | 0.008 | 0.113 | Glutamate (mGluR5) antagonist | |||
| 0.163 | 0.064 | 0.163 | Hexokinase inhibitor | |||
| 0.126 | 0.029 | 0.126 | Triose-phosphate isomerase inhibitor | |||
| 0.17 | 0.074 | 0.17 | 3C-like protease (Human coronavirus) inhibitor | |||
| 0.101 | 0.005 | 0.101 | Dihydroorotase inhibitor | |||
| 0.101 | 0.007 | 0.11 | Sphingosine kinase inhibitor | 0.11 0.006 DBMET01532 | DBMET01532 | |
| 0.234 | 0.14 | 0.234 | Vasodilator, peripheral | |||
| 0.096 | 0.005 | 0.096 | Benzodiazepine inverse agonist | 0.065 0.011 DBMET01532 | ||
| 0.263 | 0.172 | 0.263 | Analgesic | |||
| 0.092 | 0.004 | 0.092 | GABA uptake inhibitor | |||
| 0.093 | 0.006 | 0.093 | Nicotinic acid receptor 2 agonist | |||
| 0.095 | 0.009 | 0.095 | Diacylglycerol O-acyltransferase inhibitor | |||
| 0.1 | 0.015 | 0.1 | Peroxisome proliferator-activated receptor gamma antagonist | |||
| 0.134 | 0.049 | 0.134 | Cystathionine beta-synthase inhibitor | |||
| 0.086 | 0.003 | 0.086 | CF transmembrane conductance regulator antagonist | 0.053 0.006 DBMET01532 | ||
| 0.097 | 0.016 | 0.097 | GABA receptor antagonist | |||
| 0.093 | 0.014 | 0.093 | Peroxisome proliferator-activated receptor alpha agonist | |||
| 0.083 | 0.004 | 0.083 | Retinoic acid receptor agonist | 0.027 0.012 DBMET01532 | ||
| 0.118 | 0.04 | 0.118 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | |||
| 0.195 | 0.118 | 0.225 | Hypoglycemic | 0.225 0.093 DBMET01532 | DBMET01532 | |
| 0.199 | 0.122 | 0.199 | Neuropeptide Y2 antagonist | |||
| 0.107 | 0.031 | 0.107 | Macrophage migration inhibitory factor inhibitor | 0.071 0.064 DBMET01532 | ||
| 0.122 | 0.046 | 0.128 | Xanthine oxidase inhibitor | 0.128 0.044 DBMET01532 | DBMET01532 | |
| 0.285 | 0.211 | 0.285 | Caspase 9 stimulant | |||
| 0.151 | 0.077 | 0.151 | Protein-tyrosine phosphatase inhibitor | 0.12 0.113 DBMET01532 | ||
| 0.102 | 0.029 | 0.102 | Glutamate decarboxylase inhibitor | |||
| 0.124 | 0.053 | 0.124 | GABA receptor agonist | |||
| 0.089 | 0.019 | 0.089 | GABA A receptor antagonist | |||
| 0.113 | 0.043 | 0.113 | Uric acid excretion stimulant | |||
| 0.112 | 0.043 | 0.112 | Electrolyte absorption antagonist | |||
| 0.077 | 0.009 | 0.077 | G protein-coupled receptor agonist | |||
| 0.178 | 0.111 | 0.215 | Hypolipemic | 0.215 0.085 DBMET01532 | DBMET01532 | |
| 0.082 | 0.016 | 0.082 | Potassium channel intermediate-conductance Ca-activated blocker | |||
| 0.097 | 0.032 | 0.097 | Keratolytic | 0.094 0.034 DBMET01532 | ||
| 0.159 | 0.096 | 0.159 | Succinate dehydrogenase inhibitor | |||
| 0.077 | 0.015 | 0.077 | Aconitate hydratase inhibitor | |||
| 0.087 | 0.025 | 0.087 | Orexin receptor 1 antagonist | |||
| 0.144 | 0.084 | 0.144 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | |||
| 0.114 | 0.056 | 0.114 | Electron transport complex I inhibitor | 0.102 0.077 DBMET01532 | ||
| 0.069 | 0.012 | 0.069 | Heparanase inhibitor | |||
| 0.064 | 0.008 | 0.064 | Retinoic acid alpha receptor agonist | 0.037 0.031 DBMET01532 | ||
| 0.137 | 0.084 | 0.137 | Ca2+-transporting ATPase inhibitor | |||
| 0.095 | 0.042 | 0.095 | Glutathione S-transferase inhibitor | |||
| 0.086 | 0.034 | 0.1 | Leukotriene synthesis inhibitor | 0.1 0.026 DBMET01532 | DBMET01532 | |
| 0.054 | 0.002 | 0.054 | Nicotinic acid receptor 1 antagonist | |||
| 0.085 | 0.034 | 0.085 | Amidase inhibitor | |||
| 0.19 | 0.139 | 0.19 | DNA synthesis inhibitor | |||
| 0.059 | 0.01 | 0.063 | Sphingosine kinase 1 inhibitor | 0.063 0.008 DBMET01532 | DBMET01532 | |
| 0.107 | 0.06 | 0.107 | Beta glucuronidase inhibitor | |||
| 0.24 | 0.194 | 0.24 | Transcription factor inhibitor | |||
| 0.145 | 0.099 | 0.157 | Dual specificity phosphatase inhibitor | 0.157 0.087 DBMET01532 | DBMET01532 | |
| 0.058 | 0.012 | 0.058 | TRPM8 blocker | |||
| 0.05 | 0.003 | 0.05 | Retinoic acid gamma receptor agonist | 0.026 0.009 DBMET01532 | ||
| 0.11 | 0.064 | 0.11 | GABA C receptor antagonist | |||
| 0.048 | 0.004 | 0.048 | 5 Lipoxygenase activating protein inhibitor | 0.016 0.006 DBMET01532 | ||
| 0.204 | 0.159 | 0.204 | Thyroid hormone antagonist | |||
| 0.223 | 0.178 | 0.223 | Histamine release inhibitor | |||
| 0.05 | 0.006 | 0.05 | Kynurenine 3 monooxygenase inhibitor | |||
| 0.075 | 0.031 | 0.075 | Glutamate (mGluR6) antagonist | |||
| 0.101 | 0.058 | 0.101 | Sphingomyelinase inhibitor | |||
| 0.047 | 0.004 | 0.047 | Nicotinic acid receptor 2 antagonist | |||
| 0.2 | 0.157 | 0.2 | Nootropic | |||
| 0.073 | 0.03 | 0.073 | Biliverdin reductase inhibitor | |||
| 0.101 | 0.059 | 0.101 | UDP-glucose 4-epimerase inhibitor | |||
| 0.093 | 0.052 | 0.093 | NADH dehydrogenase inhibitor | |||
| 0.133 | 0.092 | 0.133 | Pregnane X receptor agonist | |||
| 0.1 | 0.059 | 0.1 | Creatine kinase inhibitor | |||
| 0.073 | 0.033 | 0.073 | DNA gyrase inhibitor | |||
| 0.074 | 0.035 | 0.074 | Glutamate (mGluR7) antagonist | |||
| 0.064 | 0.025 | 0.064 | Dihydroorotate dehydrogenase inhibitor | |||
| 0.072 | 0.034 | 0.072 | MDM2 inhibitor | |||
| 0.053 | 0.015 | 0.053 | Kinesin-like protein 1 inhibitor | |||
| 0.053 | 0.015 | 0.053 | Kinesin antagonist | |||
| 0.047 | 0.01 | 0.047 | Dipeptidyl peptidase II inhibitor | |||
| 0.043 | 0.007 | 0.043 | Calcium-independent phospholipase A2 inhibitor | |||
| 0.044 | 0.009 | 0.044 | Purinergic P2Y14 antagonist | |||
| 0.194 | 0.159 | 0.204 | Hypoxia-inducible factor 1 alpha inhibitor | 0.204 0.147 DBMET01532 | DBMET01532 | |
| 0.049 | 0.016 | 0.049 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | |||
| 0.046 | 0.014 | 0.046 | Histone deacetylase 4 inhibitor | |||
| 0.047 | 0.016 | 0.047 | Retinoid X receptor antagonist | |||
| 0.07 | 0.04 | 0.07 | Orexin receptor antagonist | |||
| 0.048 | 0.019 | 0.048 | DNA gyrase subunit A inhibitor | |||
| 0.042 | 0.013 | 0.059 | Catechol O-methyltransferase inhibitor | 0.059 0.007 DBMET01532 | DBMET01532 | |
| 0.191 | 0.162 | 0.191 | Thyroid hormone beta antagonist | |||
| 0.041 | 0.013 | 0.041 | Retinoid X alpha receptor antagonist | |||
| 0.097 | 0.072 | 0.097 | Adenylate kinase inhibitor | |||
| 0.129 | 0.103 | 0.129 | Phospholipase A2 inhibitor | |||
| 0.083 | 0.058 | 0.083 | GABA A receptor agonist | |||
| 0.226 | 0.201 | 0.226 | Antibacterial | |||
| 0.041 | 0.017 | 0.041 | Peroxisome proliferator-activated receptor delta agonist | |||
| 0.058 | 0.035 | 0.058 | Pregnane X receptor antagonist | |||
| 0.152 | 0.13 | 0.152 | Insulin sensitizer | |||
| 0.032 | 0.01 | 0.032 | Retinoid X gamma receptor antagonist | |||
| 0.057 | 0.035 | 0.057 | Adenine nucleotide translocase inhibitor | |||
| 0.093 | 0.073 | 0.093 | GABA C receptor rho-1 antagonist | |||
| 0.05 | 0.03 | 0.05 | Phosphorylase inhibitor | |||
| 0.069 | 0.049 | 0.069 | Peroxisome proliferator-activated receptor gamma agonist | |||
| 0.067 | 0.048 | 0.067 | Potassium channel large-conductance Ca-activated activator | |||
| 0.037 | 0.018 | 0.037 | Peroxisome proliferator-activated receptor delta antagonist | |||
| 0.033 | 0.014 | 0.033 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | |||
| 0.082 | 0.063 | 0.082 | D-Ala-D-Ala ligase inhibitor | |||
| 0.038 | 0.019 | 0.038 | Glucose-dependent insulinotropic receptor agonist | |||
| 0.119 | 0.1 | 0.119 | Sphingosine 1-phosphate receptor 2 antagonist | |||
| 0.039 | 0.022 | 0.039 | Orexin receptor 2 antagonist | |||
| 0.069 | 0.052 | 0.069 | Secretase beta inhibitor | |||
| 0.054 | 0.036 | 0.054 | Prostaglandin antagonist | |||
| 0.071 | 0.055 | 0.071 | Porphobilinogen synthase inhibitor | |||
| 0.044 | 0.028 | 0.044 | Guanylate cyclase stimulant | |||
| 0.045 | 0.029 | 0.045 | Stearoyl-CoA desaturase inhibitor | |||
| 0.025 | 0.009 | 0.025 | Retinoic acid alpha receptor antagonist | |||
| 0.024 | 0.009 | 0.024 | Retinoic acid receptor antagonist | |||
| 0.041 | 0.027 | 0.041 | Nicotinic acid receptor 1 agonist | |||
| 0.088 | 0.074 | 0.088 | Aminopeptidase B inhibitor | |||
| 0.047 | 0.034 | 0.047 | Carnitine palmitoyltransferase 1B inhibitor | |||
| 0.026 | 0.013 | 0.026 | Peroxisome proliferator-activated receptor alpha antagonist | |||
| 0.029 | 0.017 | 0.029 | NMDA 2D receptor antagonist | |||
| 0.022 | 0.011 | 0.022 | Retinoid X beta receptor antagonist | |||
| 0.042 | 0.031 | 0.042 | Guanylate cyclase inhibitor | |||
| 0.015 | 0.005 | 0.015 | Thrombopoietin agonist | |||
| 0.164 | 0.154 | 0.164 | Interleukin agonist | |||
| 0.043 | 0.033 | 0.043 | Glutamate (mGluR group III) antagonist | |||
| 0.091 | 0.081 | 0.091 | Carbonic anhydrase XV inhibitor | |||
| 0.025 | 0.016 | 0.025 | Glutamate (mGluR1) agonist | |||
| 0.127 | 0.118 | 0.127 | Interferon gamma antagonist | |||
| 0.079 | 0.07 | 0.079 | Transforming growth factor beta 3 antagonist | |||
| 0.052 | 0.044 | 0.052 | Xanthine dehydrogenase inhibitor | |||
| 0.07 | 0.062 | 0.07 | GABA aminotransferase inhibitor | |||
| 0.05 | 0.043 | 0.05 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | |||
| 0.013 | 0.007 | 0.013 | Retinoic acid beta receptor antagonist | |||
| 0.023 | 0.016 | 0.023 | Retinoid X gamma receptor agonist | |||
| 0.138 | 0.132 | 0.138 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | |||
| 0.057 | 0.052 | 0.057 | Prostaglandin F2 alpha antagonist | |||
| 0.012 | 0.008 | 0.012 | Retinoic acid receptor gamma antagonist | |||
| 0.034 | 0.03 | 0.034 | Glutamate (mGluR8) antagonist | |||
| 0.02 | 0.016 | 0.02 | Retinoid X beta receptor agonist | |||
| 0.06 | 0.057 | 0.06 | Phenylalanine 4-hydroxylase inhibitor | |||
| 0.031 | 0.028 | 0.031 | RNA-directed RNA polymerase inhibitor | |||
| 0.079 | 0.076 | 0.12 | MAO B inhibitor | 0.12 0.05 DBMET01532 | DBMET01532 | |
| 0.02 | 0.017 | 0.02 | Lysophosphatidic acid 1 receptor antagonist | |||
| 0.035 | 0.033 | 0.035 | Glutamate (mGluR8) agonist | |||
| 0.066 | 0.063 | 0.066 | Glutamate dehydrogenase inhibitor | |||
| 0.03 | 0.028 | 0.03 | Glutamate (mGluR3) agonist | |||
| 0.045 | 0.043 | 0.045 | Topoisomerase II beta inhibitor | |||
| 0.033 | 0.031 | 0.033 | Glutamate (mGluR3) antagonist | |||
| 0.08 | 0.114 | 0.12 | MAO inhibitor | 0.12 0.075 DBMET01532 | DBMET01532 | |
| 0.108 | 0.144 | 0.184 | Hemostatic | 0.184 0.04 DBMET01532 | DBMET01532 | |
| 0.088 | 0.151 | 0.126 | Protein kinase stimulant | 0.126 0.087 DBMET01532 | DBMET01532 | |
| 0.179 | 0.246 | 0.23 | DNA directed DNA polymerase inhibitor | 0.23 0.205 DBMET01532 | DBMET01532 | |
| 0.048 | 0.117 | 0.072 | HIV-1 integrase inhibitor | 0.072 0.045 DBMET01532 | DBMET01532 | |
| 0.052 | 0.14 | 0.101 | 5-Lipoxygenase inhibitor | 0.101 0.063 DBMET01532 | DBMET01532 | |
| 0.152 | 0.248 | 0.192 | Antithrombotic | 0.192 0.188 DBMET01532 | DBMET01532 | |
| 0.129 | 0.232 | 0.235 | Lipoxygenase inhibitor | 0.235 0.111 DBMET01532 | DBMET01532 | |
| 0.148 | 0.278 | 0.271 | Apoptosis antagonist | 0.271 0.107 DBMET01532 | DBMET01532 | |
| 0.082 | 0.231 | 0.174 | Nitric oxide antagonist | 0.174 0.079 DBMET01532 | DBMET01532 | |
| 0.051 | 0.223 | 0.081 | Transcription factor NF kappa B stimulant | 0.081 0.068 DBMET01532 | DBMET01532 | |
| 0.016 | 0.197 | 0.055 | HIV-1 integrase (Strand Transfer) inhibitor | 0.055 0.045 DBMET01532 | DBMET01532 | |
| 0.118 | 0.304 | 0.473 | Alpha-glucosidase inhibitor | 0.473 0.088 DBMET01532 | DBMET01532 | |
| 0.019 | 0.213 | 0.072 | HIV-1 integrase (3'-Processing) inhibitor | 0.072 0.038 DBMET01532 | DBMET01532 | |
| 0.073 | 0.272 | 0.178 | Hepatoprotectant | 0.178 0.082 DBMET01532 | DBMET01532 | |
| 0.153 | 0.383 | 0.262 | Calcium channel L-type activator | 0.262 0.193 DBMET01532 | DBMET01532 | |
| 0.063 | 0.298 | 0.154 | Antimitotic | 0.154 0.118 DBMET01532 | DBMET01532 | |
| 0.024 | 0.288 | 0.097 | Topoisomerase I inhibitor | 0.097 0.072 DBMET01532 | DBMET01532 | |
| 0.027 | 0.321 | 0.08 | ATPase (Vacuolar H+) inhibitor | 0.08 0.078 DBMET01532 | DBMET01532 | |
| 0.032 | 0.405 | 0.146 | DNA polymerase I inhibitor | 0.146 0.052 DBMET01532 | DBMET01532 | |
| 0.039 | 0.476 | 0.251 | Antioxidant | 0.251 0.083 DBMET01532 | DBMET01532 | |
| 0.019 | 0.582 | 0.218 | Free radical scavenger | 0.218 0.084 DBMET01532 | DBMET01532 | |
| 0.055 | 0.622 | 0.306 | Apoptosis agonist | 0.306 0.168 DBMET01532 | DBMET01532 | |
| 0.005 | 0.819 | 0.117 | Lipid peroxidase inhibitor | 0.117 0.096 DBMET01532 | DBMET01532 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |